medical-device-investing Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
medical-device-investing Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
medical-device-investing Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
medical-device-investing Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse Technology
medical-device-investing Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
medical-device-investing Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
medical-device-investing Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
medical-device-investing Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
medical-device-investing Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
medical-device-investing Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
medical-device-investing Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635
medical-device-investing Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule Study
Rio Silver Launches Metallurgical Program to De-Risk Processing and Optimize Silver Recoveries at Maria Norte
